Effect of LY2062430 on the Progression of Alzheimer's Disease

NCT00904683 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1040

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: LY2062430
DRUG: Placebo

Sponsor

Eli Lilly and Company